ReviewReviews in cardiovascular medicine2022
Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention.
Review in Reviews in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials.European heart journal. Cardiovascular pharmacotherapy · 2026Pooled it
- Impact of Mild Hypothermia As Adjunctive Therapy in Patients With ST-Elevation Myocardial Infarction: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Pooled it
- Managing bleeds on anticoagulant therapy: a practical guide for clinicians.European heart journal. Acute cardiovascular care · 2026Review
- Ticagrelor-based DAPT after CABG: in whom and for how long?Journal of thrombosis and thrombolysis · 2026Article
- Single vs. dual antiplatelet therapy in patients with severe peripheral arterial disease undergoing transcatheter aortic valve implantation: insights from the Hostile registry.European heart journal. Cardiovascular pharmacotherapy · 2025Observational
- Sex-related variations in platelet reactivity in presence or absence of antiplatelet therapy.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- Antiplatelet Therapy in Myocardial Bridge: Insights From the RIALTO Registry.Journal of the American Heart Association · 2025Observational
- Direct oral anticoagulants in stroke prevention of atrial fibrillation patients: can we rely on them in all clinical scenarios?Future cardiology · 2025Article
- Combining Colchicine and Antiplatelet Therapy to Tackle Atherothrombosis: A Paradigm in Transition?International journal of molecular sciences · 2025Review
- Antiplatelet Therapy in Low-Platelet-Count Patients After Percutaneous Coronary Intervention for Acute Coronary Syndromes.Journal of clinical medicine · 2025Review
- Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospital.Journal of thrombosis and thrombolysis · 2025Article
- Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2024Review
- Editorial: Precision medicine for antithrombotic therapy in patients after percutaneous coronary interventions.Frontiers in cardiovascular medicine · 2023Article
- De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?Frontiers in cardiovascular medicine · 2022Review
- Feasibility, effectiveness, and safety of edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study.Frontiers in cardiovascular medicine · 2022Article
- Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?Frontiers in cardiovascular medicine · 2022Review
- Acute Coronary Syndrome in Essential Thrombocythemia and Polycythemia Vera.Heart views : the official journal of the Gulf Heart AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous coronary intervention (PCI) is considered a relatively safe procedure associated with low rates of complications, but is inevitably associated with short and mid-to-long term increased bleeding risk. Besides the short term risk associated with the arterial access to perform PCI, enhanced bleeding risk persists for several months, given the need for antithrombotic therapy to prevent procedure-related thrombotic complications as well as ischemic recurrences. Bleeding is a powerful harbinger of adverse outcomes. This awareness has fuelled intense research on bleeding reduction strategies, including new PCI devices and techniques as well as new medications and antithrombotic regimens. We here review the mechanisms and prevalence of bleeding in PCI patients, discuss the available evidence from a practical point of view, and explore future perspectives on how to treat and prevent bleeding complications in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.